CTLA4 and hematologic disorder: During the past decade, immune checkpoint blockade therapies, including anti-PD-1 (pembrolizumab, nivolumab, cemiplimab and tislelizumab), anti-PD-L1 (atezolizumab, avelumab, and durvalumab), and anti-CTLA-4 (ipilimumab), have significantly revolutionized the treatment approach for hematologic malignancies.